Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | USP2 | O75604 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 1/20 | 0.85 |
| ▸ | HPGD | P15428 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182113 | 0.92 | LMNA (1.00) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939875 | 0.92 | IMPDH2 (0.72) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939840 | 0.92 | IMPDH2 (0.72) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL2607554 | 0.90 | HPGD (0.81) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939833 | 0.88 | KDM4E (0.67) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939852 | 0.88 | IMPDH2 (0.81) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939841 | 0.88 | IMPDH2 (0.81) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939837 | 0.88 | IMPDH2 (0.81) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL16939827 | 0.88 | MAPT (0.66) | KDM4EUSP2ALDH1A1LMNAESR1 | |
| SCHEMBL15597537 | 0.88 | KDM4E (0.74) | KDM4EUSP2ALDH1A1LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010108187-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KDM4E 1620/4885USP2 3758/4885ALDH1A1 45/4885 |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | IMPDH1, IMPDH2, IMPA1 | KDM4E 2734/4885USP2 4322/4885ALDH1A1 57/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KDM4E 1620/4885USP2 3758/4885ALDH1A1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.